Mucin Glycosylating Enzymes in Head and Neck Cancers

Glycosyltion Enzymes and Function Abnormalities Clinical Trial

Official title:

Expression of Mucin Glycosylating Enzymes in Head and Neck Cancers and Its Correlation With Clinico-pathological Parameters.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01976377
• Other study ID #: 201307074RIND
• Status: Recruiting
• Phase: N/A
• First received: October 22, 2013
• Last updated: December 13, 2016
• Start date: October 2013
• Est. completion date: October 2017

Study information

• Verified date: December 2016
• Source: National Taiwan University Hospital
• Contact: Pei-Jen Lou, M.D, Ph.D
• Phone: 886-972651527
• Email: pjlou[@]ntu.edu.tw
• Is FDA regulated: No
• Health authority: Taiwan: Ministry of Health and Welfare
• Study type: Observational

Clinical Trial Summary

Head and neck squamous cell carcinoma(HNSCC) is the fourth common malignancy in Taiwan. It accounts for 5.8% of all cancers and causes 2,463 deaths per year. Aberrant glycosylation is the hallmark of most human cancers, including HNSCC, and affects many cellular properties. This study is aimed at exploring the role of mucin glycosylating enzymes in HNSCC.

Description:

Glycosylation is the most common post-translational modification of proteins. Aberrant glycosylation is the hallmark of most human cancers and affect many cellular properties, including cell proliferation, apoptosis, differentiation, transformation, migration and immune response.

Though widely explored in various human cancers, the role of mucin glycosylating enzymes in HNSCC has not been elucidated. Our aims is to analyze the expression patterns of mucin glycosylating enzymes in HNSCC tissues. Furthermore, we will correlate the expression levels of mucin glycosylating enzymes with clinical characteristics of HNSCC patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: October 2017
• Est. primary completion date: October 2017
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years to 90 Years

Eligibility

Inclusion Criteria:

• Head and neck cancer patients receiving operation in National Taiwan University Hospital

Exclusion Criteria:

• Recurrence or non-operable patients

Study Design

Observational Model: Case Control, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Glycosyltion Enzymes and Function Abnormalities
• Head and Neck Neoplasms

Locations

Country	Name	City	State
Taiwan	National Taiwan University	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measure the expression of mucin glycosylating in head and neck cancer		1~5 years after patient received surgery	Yes